Ajanta Pharma Limited (NSE: AJANTAPHARMA) is an Indian pharmaceutical company that specializes in the production and distribution of generic drugs. The company has reported its financial results for the third quarter (Q3) of fiscal year 2023 (FY23) and for the first nine months (9M) of the fiscal year. The revenue from operations in Q3FY23 was Rs 972 crore, an increase of 16% from the previous quarter (Rs 838 crore). The revenue from operations for the first nine months of the fiscal year was Rs 2,861 crore, up 16% from the previous year (Rs 2,471 crore).<\/p>\n\n\n\n
The EBITDA in Q3FY23 was Rs 170 crore, a decrease of 29% from the previous quarter (Rs 240 crore). The EBITDA margin was 17% of revenue from operations. The adjusted EBITDA, after adjusting for the forex derivative loss, was Rs 207 crore, a decrease of 14% from the previous quarter (Rs 240 crore). The adjusted EBITDA margin was 21% of revenue from operations.<\/p>\n\n\n\n
For the first nine months of the fiscal year, the EBITDA was Rs 588 crore, a decrease of 19% from the previous year (Rs 723 crore). The EBITDA margin was 21% of revenue from operations. The adjusted EBITDA, after adjusting for the forex derivative loss, was Rs 631 crore, a decrease of 13% from the previous year (Rs 723 crore). The adjusted EBITDA margin was 22% of revenue from operations. The Profit After Tax in Q3FY23 was Rs 135 crore, a decrease of 30% from the previous quarter (Rs 192 crore). The PAT margin was 14% of revenue from operations. For the first nine months of the fiscal year, the PAT was Rs 466 crore, a decrease of 17% from the previous year (Rs 561 crore). The PAT margin was 16% of revenue from operations. The company has reported an EPS of Rs. 10.50 for the period ended December 31, 2022, a decrease of 14% from the previous quarter (Rs. 12.22). The EPS has decreased by 29% compared to the same period in the previous year (Rs. 14.77).<\/p>\n\n\n\n
Ajanta Pharma Ltd reported a 16% increase in revenue from operations in Q3FY23 and 9MFY23, but a decrease in EBITDA and PAT compared to the same period in the previous year. The adjusted EBITDA margin was slightly higher, indicating improved operational efficiency.<\/p>\n","protected":false},"excerpt":{"rendered":"
Ajanta Pharma Limited (NSE: AJANTAPHARMA) is an Indian pharmaceutical company that specializes in the production and distribution of generic drugs. The company has reported its financial results for the third quarter (Q3) of fiscal year 2023 (FY23) and for the first nine months (9M) of the fiscal year. The revenue from operations in Q3FY23 was […]<\/p>\n","protected":false},"author":1932,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,5747],"tags":[1115],"class_list":["post-141220","post","type-post","status-publish","format-standard","hentry","category-earnings","category-healthcare-stocks","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":142658,"url":"https:\/\/alphastreet.com\/india\/vedant-fashions-q3fy23-net-profit-rises-by-18-per-cent\/","url_meta":{"origin":141220,"position":0},"title":"Vedant Fashions Q3FY23 net profit rises by 18 per cent","author":"Chirag Gupta","date":"February 23, 2023","format":false,"excerpt":"Vedant Fashions, which owns the ethnic wear brand Manyavar, has recorded a 17.6 percent rise in consolidated net profit at Rs 150.35 crore in the third quarter (Q3) ended December 31 of the current fiscal 2022-23 as against the profit of Rs 127.80 crore in the same period of the\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"earnings preview","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2019\/04\/Earnings-preview-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":140759,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-limited-nse-auropharma-q3-fy23-results-out-total-income-rises-7-yoy\/","url_meta":{"origin":141220,"position":1},"title":"Aurobindo Pharma Limited (NSE: AUROPHARMA): Q3 FY23 Results Out; Total Income Rises 7% YoY","author":"Divyansh_Kasana","date":"February 9, 2023","format":false,"excerpt":"Aurobindo Pharma Limited (NSE: AUROPHARMA) is a pharmaceutical company based in Hyderabad, India. The company was founded in 1986 and has since grown to become one of the largest pharmaceutical companies in India, with a presence in over 150 countries. Aurobindo Pharma produces a wide range of generic and specialty\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/b7778d7c-e8b5-4ee8-8702-740018666b7d.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143079,"url":"https:\/\/alphastreet.com\/india\/earnings-kansai-nerolac-paints-ltd-nsekansainer-q3fy23-results-out-total-income-rise-0-8-yoy\/","url_meta":{"origin":141220,"position":2},"title":"Earnings | Kansai Nerolac Paints Ltd. (NSE:KANSAINER): Q3FY23 Results Out; Total Income rise 0.8% YoY","author":"Divyansh_Kasana","date":"March 1, 2023","format":false,"excerpt":"Kansai Nerolac Paints Ltd. (NSE:KANSAINER) is one of the leading paint companies in India, offering a wide range of decorative and industrial paints. The company was established in 1920 and is headquartered in Mumbai, India. It is a subsidiary of Kansai Paint Co. Ltd., a Japanese paint manufacturing company. Kansai\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":141871,"url":"https:\/\/alphastreet.com\/india\/blue-star-ltd-nse-bluestarco-q3-fy23-results-out-total-income-rise-18-yoy\/","url_meta":{"origin":141220,"position":3},"title":"Blue star Ltd. (NSE: BLUESTARCO): Q3 FY23 Results Out; Total Income rise 18% YoY","author":"Divyansh_Kasana","date":"February 15, 2023","format":false,"excerpt":"Bluestar Ltd. (NSE: BLUESTARCO) is a multinational company based in India that provides a range of solutions in the fields of air conditioning and commercial refrigeration. The company offers a wide range of products and services including central air conditioning systems, room air conditioners, refrigeration systems, cold storage, and building\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":143030,"url":"https:\/\/alphastreet.com\/india\/earnings-eid-parry-india-ltd-nseeidparry-q3fy23-results-out-total-income-rise-50-yoy\/","url_meta":{"origin":141220,"position":4},"title":"Earnings | EID Parry (India) Ltd (NSE:EIDPARRY): Q3FY23 Results Out; Total Income rise 50% YoY","author":"Divyansh_Kasana","date":"February 28, 2023","format":false,"excerpt":"EID Parry (India) Ltd (NSE:EIDPARRY) is a leading Indian company that is primarily involved in the production and marketing of sugar, bio-products, and nutraceuticals. The company was founded in 1788 and is headquartered in Chennai, India. EID Parry has a strong presence in the agriculture and food sectors, and its\u2026","rel":"","context":"In "Agricultural Products"","block_context":{"text":"Agricultural Products","link":"https:\/\/alphastreet.com\/india\/category\/agricultural-products\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":141218,"url":"https:\/\/alphastreet.com\/india\/affle-india-ltd-nse-affle-q3-fy23-results-out-total-income-rises-11-yoy\/","url_meta":{"origin":141220,"position":5},"title":"AFFLE (INDIA) LTD. (NSE: AFFLE): Q3 FY23 Results Out; Total Income Rises 11% YoY","author":"Divyansh_Kasana","date":"February 13, 2023","format":false,"excerpt":"Affle (India) Ltd (NSE:AFFLE) is an internet software and services firm that recently announced its Q3FY23 results. The results showed strong growth in both revenue and profits. In Q3FY23, revenue from operations was Rs 376.1 crore, an increase of 6.1% on a quarter-on-quarter basis and 10.8% on a year-on-year basis.\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/141220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=141220"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/141220\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=141220"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=141220"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=141220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}